Efficacy and Toxicity of Heparin in Relation to Age and Sex
about
Retroperitoneal haemorrhage and neuropathy complicating anticoagulant therapySpontaneous intraspinal hemorrhage causing paraplegia: a complication of heparin therapyDrug surveillance data in a Canadian hospital.Risk of complications during intravenous heparin therapyEffects of increasing left ventricular filling. Pressure in patients with acute myocardial infarction.Anticoagulant drugs in the elderly: the risks usually outweight the benefits.Low-molecular-weight heparin for the treatment of venous thromboembolism in the elderly.Computer analysis of epidemiologic data on effect of drugs on hospital patients.Designing and evaluating a clustering system for organizing and integrating patient drug outcomes in personal health messagesTotal lung collapse after pulmonary infarction.Pulmonary embolism: a review of medical treatment.Gender differences in the effects of cardiovascular drugs.Anticoagulants in venous thromboembolism. Prophylactic and therapeutic use.Pharmacology and aging.Predictors of hospital mortality in older patients with subdural hematoma.Laboratory control of heparin therapy.Unsuitability of evacuated tubes for monitoring heparin therapy by activated partial thromboplastin timeAge as a determinant of sensitivity to warfarin.Editorial: Venous thrombosis--newer diagnostic and therapeutic approaches.Recognition of unwanted drug effects.
P2860
Q28363434-E8983917-4062-45B5-8135-4F176905B86CQ28364145-AA135014-2703-4F9A-8F8D-8005C4816472Q33186180-A67A94E2-1104-4187-8474-80AA2D85F7E4Q34111166-D0C88D35-B4A3-44E0-A2A3-53AA82C0702FQ35579384-3AE2B2C6-01A5-4EC7-9717-E3EF69F56660Q35704525-FDC7CC2A-26D7-45A1-9728-6D7E4839CCABQ36022983-6378AA63-BC7B-41E7-899E-F60E5431DCB4Q36074990-DF517106-478C-46AD-BE2E-EBD8CB974FECQ36519059-C3E6BD91-8D8F-43A0-8089-97E07855C252Q36575639-3BD5FD5F-D7DC-44DC-A460-42BF16401598Q36650852-8DB3AA5C-8EE3-4F96-864B-54013DB2C995Q39193538-0EBC6123-1B67-40AB-96B3-372B40AC461FQ39935072-14EBF70C-2669-4379-917D-2B96503F5B2BQ40326082-CA95C8A0-B360-43C1-A872-DF2EED1E9F79Q40608750-1E98803D-7F37-4706-BCAC-C72443F23878Q41254745-6A27985F-D0D0-45FC-AD18-29F94D420125Q41807792-E464107F-B554-40B2-BA37-A8D0E284C22AQ41946702-951BEE1E-DEF3-4D08-B287-E361AF48C9A5Q42790240-3CE0DD92-B583-4676-8097-1BA6E51DDE6EQ49179323-D63DBBA3-AE82-490E-8985-E2072F7F3A85
P2860
Efficacy and Toxicity of Heparin in Relation to Age and Sex
description
1968 nî lūn-bûn
@nan
1968年の論文
@ja
1968年学术文章
@wuu
1968年学术文章
@zh
1968年学术文章
@zh-cn
1968年学术文章
@zh-hans
1968年学术文章
@zh-my
1968年学术文章
@zh-sg
1968年學術文章
@yue
1968年學術文章
@zh-hant
name
Efficacy and Toxicity of Heparin in Relation to Age and Sex
@en
Efficacy and Toxicity of Heparin in Relation to Age and Sex
@nl
type
label
Efficacy and Toxicity of Heparin in Relation to Age and Sex
@en
Efficacy and Toxicity of Heparin in Relation to Age and Sex
@nl
prefLabel
Efficacy and Toxicity of Heparin in Relation to Age and Sex
@en
Efficacy and Toxicity of Heparin in Relation to Age and Sex
@nl
P2093
P1476
Efficacy and Toxicity of Heparin in Relation to Age and Sex
@en
P2093
Dennis Slone
Ivan T. Borda
Samuel Shapiro
P304
P356
10.1056/NEJM196808082790603
P407
P50
P577
1968-08-08T00:00:00Z